Evidence-Based Hormone Therapies

Vasopressin

Information about its roles

  1. Water retention in skin and blood vessels. Vasopressin’s major role is to keep water in the body. Two-thirds of the human body is made up of water and vasopressin is the most potent hormone to keep water inside of the body. To achieve this, vasopressin blocks water excretion in the kidneys in a different way than aldosterone does. Aldosterone keeps water in the body indirectly through sodium retention, which attracts water by osmotic forces), whilst vasopressin makes the kidneys directly retain water, without retaining sodium.
  2. Prevention of blood loss: In case of bleeding (hemorrhages), vasopressin considerably helps to keep blood inside of the capillaries and blood vessels, preventing any excessive blood loss, a property that is life-saving in surgery and physical trauma.
  3. Memory improvement: Vasopressin improves memory and in particular learning. People with vasopressin deficiency are forgetful.
Healthy adults – UROLOGICAL SYSTEM
Urine flow: the improvement (reduction) with oral desmopressin treatment in healthy adults (1 reference)
  1. Nicholson AN1, Turner C. Anti-diuretic for operational aircrew: effects of desmopressin on urine flow, cognition, and sleepiness. Aviat Space Environ Med. 2005 Aug;76(8):760-5.
Diuresis, urine volume: the reduction with IV desmopressin treatment in healthy individuals (1 reference)
  1. Juul KV, Erichsen L, Robertson GL. Temporal delays and individual variation in antidiuretic response to desmopressin. Am J Physiol Renal Physiol. 2013 Feb 1;304(3):F268-78.
Diuresis, urine volume: the improvement (reduction) In healthy adults with improved absorption of oral desmopressin in fasting state (1 reference)
  1. Rittig S1, Jensen AR, Jensen KT, Pedersen EB. Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. Clin Endocrinol (Oxf). 1998 Feb;48(2):235-41.

 

HEMATOLOGICAL SYSTEM/HEMODYNAMIC PARAMETERS in healthy adults
Cardiovascular and coagulating effects: the improvement with IV desmopressin treatment in healthy adults (1 reference)
  1. Jacobs GE1, Hulskotte EG, van Gerven JM, Zuurman L, de Kam ML, Elassaiss-Schaap J, Ruigt G, van Pelt J, Peeters BW, Peeters PA, Burggraaf J. Desmopressin as a pharmacological tool in vasopressinergic hypothalamus-pituitary-adrenal axis modulation: neuroendocrine, cardiovascular and coagulatory effects. J Psychopharmacol. 2011 Mar;25(3):353-60.
Serum tissue-type plasminogen activator levels: the increase with intraarterial intrabrachial desmopressin n healthy young men (1 reference)
  1. Wall U, Jern S, Tengborn L, Jern C. Evidence of a local mechanism for desmopressin-induced tissue-type plasminogen activator release in human forearm. Blood. 1998 Jan 15;91(2):529-37.
Coagulation and fibrinolysis; the improvement (stimulation) with desmopressin treatment in healthy adults (2 references)
  1. Flordal PA1, Svensson J, Ljungström KG. Effects of desmopressin and dextran on coagulation and fibrinolysis in healthy volunteers. Thromb Res. 1991 Jun 1;62(5):355-64.
  2. The effects of desmopressin and dextran on hemostasis and fibrinolysis were studied in four healthy volunteers. Both drugs were compared to placebo, each volunteer being subject to four experiments. Dextran 70 (30 g i.v.) moderately decreased VIII:C and vWF:Ag and slightly increased antithrombin III, also when haemodilution and diurnal variation were considered. Desmopressin (0.3 micrograms/kg BW i.v.), alone as well as in combination with dextran, increased VIII: C, vWF:Ag, protein C and tPA and decreased PAI-1. The combination of desmopressin and dextran stimulated coagulation and fibrinolysis and might be of relevance to surgical blood loss as well as to postoperative thromboembolism.
Coagulation: the increase (of serum levels of Von Willebrand factor) with IV desmopressin treatment in healthy men (1 reference)
  1. Jilma B, Eichler HG, Vondrovec B, Breiteneder H, Kyrle PA, Kitzweger E, Kapiotis S, Speiser W. Effects of desmopressin on circulating P-selectin. Br J Haematol. 1996 May;93(2):432-6.
Prolonged bleeding (induced by hypothermia and aspirin): the improvement (reduction) with desmopressin treatment in healthy adults (1 reference)
  1. Tsui PY, Cheung CW, Lee Y, Leung SW, Ng KF. The effectiveness of low-dose desmopressin in improving hypothermia-induced impairment of primary haemostasis under influence of aspirin – a randomized controlled trial. BMC Anesthesiol. 2015 May 28;15:80

 

BRAIN:
Memory: no significant effect of intranasal desmopressin treatment in healthy subjects (1 reference)
  1. Guard O, Marchal G, Graule A, Dumas R, D’Athis P. Effects of vasopressin and desmopressin on memory. A double-blind study in 40 healthy volunteers. Neuropsychobiology. 1986;15(2):80-3.

 

Adults with UROLOGICAL disorders

 

DAYTIME URINATION

 

Overactive bladder: the improvement with oral desmopressin treatment (1 reference)
  1. Hashim H1, Malmberg L, Graugaard-Jensen C, Abrams P. Desmopressin, as a “designer-drug,” in the treatment of overactive bladder syndrome. Neurourol Urodyn. 2009;28(1):40-6.
Pollakiuria, daytime urination: the improvement (reduction) with intranasal desmopressin treatment in patients with multiple sclerosis, complaining of frequency of day time micturition (1 reference)
  1. Hoverd PA, Fowler CJ. Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998 Nov;65(5):778-80.
Bladder dysfunction (socially handicapping voidings and incontinence problems during daytime): the improvement with intranasal desmopressin treatment in patients with multiple sclerosis (1 reference)
  1. Fredrikson S. Nasal spray desmopressin treatment of bladder dysfunction in patients with multiple sclerosis. Acta Neurol Scand. 1996 Jul;94(1):31-4.

 

NIGHTTIME URINATION
Nocturia: the improvement with intranasal desmopressin treatment in female patients with multiple sclerosis (1 reference)
  1. Hilton P, Hertogs K, Stanton SL. The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. J Neurol Neurosurg Psychiatry. 1983 Sep;46(9):854-5.
Nocturia (2 or more nocturnal voids): the improvement with oral desmopressin treatment in women (5 references)
  1. Sand PK, Dmochowski RR, Reddy J, van der Meulen EA. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. J Urol. 2013 Sep;190(3):958-64.
  2. van Kerrebroeck P1, Rezapour M, Cortesse A, Thüroff J, Riis A, Nørgaard JP. Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study. Eur Urol. 2007 Jul;52(1):221-9.
  3. Hvistendahl GM1, Riis A, Nørgaard JP, Djurhuus JC. The pharmacokinetics of 400 microg of oral desmopressin in elderly patients with nocturia, and the correlation between the absorption of desmopressin and clinical effect. BJU Int. 2005 Apr;95(6):804-9.
  4. Lose G1, Lalos O, Freeman RM, van Kerrebroeck P; Nocturia Study Group. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol. 2003 Oct;189(4):1106-13.
  5. Asplund R, Sundberg B, Bengtsson P. Oral desmopressin for nocturnal polyuria in elderly subjects: a double-blind, placebo-controlled randomized exploratory study. BJU Int. 1999 Apr;83(6):591-5.
Nocturia: the improvement with oral desmopressin treatment in men (2 references)
  1. Weiss JP, Herschorn S, Albei CD, van der Meulen EA. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. J Urol. 2013 Sep;190(3):965-72.
  2. Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int. 2002 Jun;89(9):855-62.
 Nocturia: the improvement with oral desmopressin treatment in older men (3 references)
  1. Rezakhaniha B1, Arianpour N, Siroosbakhat S. Efficacy of desmopressin in treatment of nocturia in elderly men. J Res Med Sci. 2011 Apr;16(4):516-23.
  2. Johnson TM1, Burridge A, Issa MM, Miller M, Tang T, Ouslander JG. The relationship between the action of arginine vasopressin and responsiveness to oral desmopressin in older men: a pilot study. J Am Geriatr Soc. 2007 Apr;55(4):562-9.
  3. Weiss JP1, Zinner NR, Klein BM, Nørgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn. 2012 Apr;31(4):441-7
Nocturia: the improvement with intranasal desmopressin treatment in female patients (1 reference)
  1. Hilton P, Stanton SL. The use of desmopressin (DDAVP) in nocturnal urinary frequency in the female. Br J Urol. 1982 Jun;54(3):252-5.
Bladder dysfunction (nocturia and incontinence problems): the improvement with intranasal desmopressin treatment in female patients with multiple sclerosis (1 reference)
  1. Eckford SD, Carter PG, Jackson SR, Penney MD, Abrams P. An open, in-patient incremental safety and efficacy study of desmopressin in women with multiple sclerosis and nocturia. Br J Urol. 1995 Oct;76(4):459-63.
Nocturia and enuresis: the improvement (reduction) with intranasal desmopressin treatment in male and female patients with multiple sclerosis (1 reference)
  1. Eckford SD1, Swami KS, Jackson SR, Abrams PH. Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis. Br J Urol. 1994 Dec;74(6):733-5.

 

Treatment with desmopressin and another compound
Nocturia: the improvement with oral desmopressin and staggered furosemide treatment. In older men and women (1 reference)
  1. Fu FG1, Lavery HJ, Wu DL. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011 Mar;30(3):312-6.
Nocturia, nocturnal polyuria: the improvement with oral desmopressin and staggered furosemide treatment in men with benign prostatic hyperplasia (1 reference)
  1. Wang CJ1, Lin YN, Huang SW, Chang CH. Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, randomized study. J Urol. 2011 Jan;185(1):219-23.

 

HEMATOLOGICAL SYSTEM/HEMODYNAMIC PARAMETERS in adults
Bleeding, blood loss: the improvement (reduction) with IV desmopressin treatment in patients undergoing cardiac surgery (4 references)
  1. Despotis GJ, Levine V, Saleem R, Spitznagel E, Joist JH. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial. Lancet. 1999 Jul 10;354(9173):106-10.
  2. Sheridan DP1, Card RT, Pinilla JC, Harding SM, Thomson DJ, Gauthier L, Drotar D. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction. Can J Surg. 1994 Feb;37(1):33-6.
  3. Chuang HI1, Horng YJ, Li Y, Chern FC, Shieh DY, Chiou IS, Ju SS. Clinical assessment of desmopressin to reduce blood loss in patients after cardiopulmonary bypass. Ma Zui Xue Za Zhi. 1993 Mar;31(1):35-42.
  4. Salzman EW, Weinstein MJ, Weintraub RM, Ware JA, Thurer RL, Robertson L, Donovan A, Gaffney T, Bertele V, Troll J, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med. 1986 May 29;314(22):1402-6.
Bleeding, postsurgical hemorrhage: the improvement (reduction) with desmopressin treatment in patients having undergone cardiac surgery (1 reference)
  1. Gratz I, Koehler J, Olsen D, Afshar M, DeCastro N, Spagna PM, Ablaza SG, Larijani GE. The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. J Thorac Cardiovasc Surg. 1992 Nov;104(5):1417-22.
Blood loss, transfusion requirements during surgery: the improvement (reduction) with desmopressin treatment given before surgery in patients undergoing aorto-iliac graft surgery (1 reference)
  1. Lethagen S, Rugarn P, Bergqvist D. Blood loss and safety with desmopressin or placebo during aorto-iliac graft surgery. Eur J Vasc Surg. 1991 Apr;5(2):173-8.
Blood loss: the improvement (reduction) of blood loss and increases of the serum levels of Factor VIIIC and von Willebrand’s factor with high-dosed IV desmopressin treatment in patients undergoing spinal fusion for neuromuscular scoliosis (1 reference)
  1. Kobrinsky NL, Letts RM, Patel LR, Israels ED, Monson RC, Schwetz N, Cheang MS. 1-Desamino-8-D-arginine vasopressin (desmopressin) decreases operative blood loss in patients having Harrington rod spinal fusion surgery. A randomized, double-blinded, controlled trial. Ann Intern Med. 1987 Oct;107(4):446-50.
Bleeding, blood loss during surgery: the nonsignificant trend to improvement with IV desmopressin treatment in patients undergoing cardiac surgery (1 reference)
  1. Ansell J, Klassen V, Lew R, Ball S, Weinstein M, VanderSalm T, Okike N, Gratz I, Leslie J, Roberts A, et al. Does desmopressin acetate prophylaxis reduce blood loss after valvular heart operations? A randomized, double-blind study. J Thorac Cardiovasc Surg. 1992 Jul;104(1):117-23.
Bleeding, blood loss during surgery: the nonsignificant trend to improvement with IV desmopressin treatment in patients undergoing surgery for neuromuscular scoliosis (1 reference)
  1. Letts M, Pang E, D’Astous J, Jarvis J, Lawton L, Luke B, Rhine E, Menard E. The influence of desmopressin on blood loss during spinal fusion surgery in neuromuscular patients. Spine (Phila Pa 1976). 1998 Feb 15;23(4):475-8.
Bleeding, blood loss: the improvement (reduction) with IV desmopressin treatment in patients undergoing aortic valve replacement (1 reference)
  1. Steinlechner B1, Zeidler P, Base E, Birkenberg B, Ankersmit HJ, Spannagl M, Quehenberger P, Hiesmayr M, Jilma B. Patients with severe aortic valve stenosis and impaired platelet function benefit from preoperative desmopressin infusion. Ann Thorac Surg. 2011 May;91(5):1420-6.
Blood loss: the mild improvement (reduction) with desmopressin treatment in patients undergoing cardiac operations (1 reference)
  1. Casas JI, Zuazu-Jausoro I, Mateo J, Oliver A, Litvan H, Muñiz-Díaz E, Arís A, Caralps JM, Fontcuberta J. Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebo-controlled study. J Thorac Cardiovasc Surg. 1995 Oct;110(4 Pt 1):1107-17.
Bleeding, blood loss during surgery: the improvement (reduction) with IV desmopressin treatment in patients with spinal cord injury undergoing reparative surgery (1 reference)
  1. Wingate GF, Lewis VL Jr, Green D, Wiedrich TA, Koenig WJ. Desmopressin decreases operative blood loss in spinal cord injury patients having flap reconstruction of pelvic pressure sores. Plast Reconstr Surg. 1992 Feb;89(2):279-82.
Bleeding (postbiopsy): the improvement (reduction) with desmopressin treatment in adult patients undergoing biopsy of the kidney (1 reference)
  1. Manno C1, Bonifati C, Torres DD, Campobasso N, Schena FP. Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. Am J Kidney Dis. 2011 Jun;57(6):850-5.
Bleeding time: the improvement (shortening) with IV desmopressin treatment in uremic patients (2 references)
  1. Malyszko J1, Pietraszek M, Buczko W, Mysliwiec M. Study on mechanisms of a haemostatic effect of 1 deamino-8-D-arginine vasopressin (desmopressin) in uraemic patients. Folia Haematol Int Mag Klin Morphol Blutforsch. 1990;117(2):319-24.
  2. Viganò GL1, Mannucci PM, Lattuada A, Harris A, Remuzzi G. Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. Am J Hematol. 1989 May;31(1):32-5.
Bleeding time: the improvement (reduction) with desmopressin treatment in patients with liver cirrhosis (2 references)
  1. Agnelli G, Parise P, Levi M, Cosmi B, Nenci GG. Effects of desmopressin on hemostasis in patients with liver cirrhosis. Haemostasis. 1995 Sep-Oct;25(5):241-7.
  2. Cattaneo M1, Tenconi PM, Alberca I, Garcia VV, Mannucci PM. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis. Thromb Haemost. 1990 Nov 30;64(3):358-60.
Coagulation: the improvement (reduction thromboplastin time (but not prothrombin time) and increases in factor VIII and its components, von Willebrand factor and ristocetin cofactor activity) with desmopressin treatment in patients with cirrhosis (1 reference)
  1. Burroughs AK, Matthews K, Qadiri M, Thomas N, Kernoff P, Tuddenham E, McIntyre N. Desmopressin and bleeding time in patients with cirrhosis. Br Med J (Clin Res Ed). 1985 Nov 16;291(6506):1377-81.
Need for blood transfusion after surgery: the marked improvement (lower need) with intraoperative IV desmopressin treatment in patients undergoing cardiac surgery, but no reduced blood loss (1 reference)
  1. Dilthey G1, Dietrich W, Spannagl M, Richter JA. Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin. J Cardiothorac Vasc Anesth. 1993 Aug;7(4):425-30.
Need for red cell transfusion after surgery: the improvement (lower need) with intraoperative IV desmopressin treatment in patients with rheumatoid arthritis undergoing hip arthroplasty (1 reference)
  1. Leino KA1, Pälve HK, Tiusanen HT, Tuppurainen TT. The effect of desmopressin on blood loss in patients with rheumatoid arthritis undergoing hip arthroplasty. Acta Anaesthesiol Scand. 2010 Aug;54(7):863-70.
Bleeding, blood loss: the improvement with IV desmopressin treatment in patients undergoing total hip replacement for primary coxarthrosis (1 reference)
  1. Flordal PA1, Ljungström KG, Ekman B, Neander G. Effects of desmopressin on blood loss in hip arthroplasty. Controlled study in 50 patients. Acta Orthop Scand. 1992 Aug;63(4):381-5.

Read all references and abstracts

Higher quality of life and energy: the association with higher vasopressin levels (1 reference)
  1. Miwa K. Down-regulation of renin-aldosterone and antidiuretic hormone systems in patients with myalgic encephalomyelitis/chronic fatigue syndrome. J Cardiol. 2017 Apr;69(4):684-688.
Low quality of life: the improvement with vasopressin treatment (6 references)
  1. Chen SL, Huang YH, Hung TW, Ou YC. Comparison of nocturia response to desmopressin treatment in elderly men with and without nocturnal polyuria in real-life practice. Int J Clin Pract. 2016 May;70(5):372-9.
  2. Sand PK, Dmochowski RR, Reddy J, van der Meulen EA. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013 Sep;190(3):958-64.
  3. Weiss JP, Herschorn S, Albei CD, van der Meulen EA. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013 Sep;190(3):965-72.
  4. Weiss JP, Zinner NR, Klein BM, Nørgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn. 2012 Apr;31(4):441-7.
  5. Carraro A, Fano M, Cuttica M, Bernareggi V, Giusti M, Giordano G. Long-term treatment of central diabetes insipidus with oral DDAVP]. Minerva Endocrinol. 1992 Oct-Dec;17(4):189-9

Read all references and abstracts

Depression: the association with lower vasopressin levels (1 reference)
  1. Gjerris A, Hammer M, Vendsborg P, Christensen NJ, Rafaelsen OJ. Cerebrospinal fluid vasopressin–changes in depression. Br J Psychiatry. 1985 Dec;147:696-701
Anxiety: the improvement with vasopressin treatment (2 references)
  1. Gozzi M, Dashow EM, Thurm A, Swedo SE, Zink CF. Effects of oxytocin and vasopressin on preferential brain responses to negative social feedback. 2017 Jun;42(7):1409-1419.
  2. hen X, Hackett PD, DeMarco AC, Feng C, Stair S, Haroon E, Ditzen B, Pagnoni G, Rilling JK. Effects of oxytocin and vasopressin on the neural response to unreciprocated cooperation within brain regions involved in stress and anxiety in men and women. Brain Imaging Behav. 2016 Jun;10(2):581-93.
Memory loss and Alzheimer’s disease: the association with lower vasopressin levels (2 references)
  1. Raskind MA, Peskind ER, Lampe TH, Risse SC, Taborsky GJ Jr, Dorsa D. Cerebrospinal fluid vasopressin, oxytocin, somatostatin, and beta-endorphin in Alzheimer’s disease. Arch Gen Psychiatry. 1986 Apr;43(4):382-8
  2. Emsley RA, Roberts MC, Aalbers C, Taljaard FJ, Kapnias S, Pieters HC, Kotze TJ.Vasopressin secretion and memory impairment in alcoholic Korsakoff’s syndrome. Alcohol Alcohol. 1995 Mar;30(2):223-9
Memory loss: the improvement with vasopressin/desmopressin treatment (12 references)
  1. Van Londen L, Goekoop JG, Zwinderman AH, Lanser JB, Wiegant VM, De Wied D. Neuropsychological performance and plasma cortisol, arginine vasopressin and oxytocin in patients with major depression. Psychol Med. 1998 Mar;28(2):275-84
  2. Perras B, Droste C, Born J, Fehm HL, Pietrowsky R. Verbal memory after three months of intranasal vasopressin in healthy old humans. Psychoneuroendocrinology. 1997 Aug;22(6):387-96
  3. Bruins J, Kumar A, Schneider-Helmert D. Influence of desglycinamide-(arg8) vasopressin on memory in healthy subjects. Neuropsychobiology. 1990;23(2):82-8
  4. Millar K, Jeffcoate WJ, Walder CP. Vasopressin and memory: improvement in normal short-term recall and reduction of alcohol-induced amnesia. Psychol Med. 1987 May;17(2):335-41
  5. Hamburger-Bar R, Eisenberg J, Belmaker RH Animal and clinical studies of vasopressin effects on learning and memory. Isr J Med Sci. 1987 Jan-Feb;23(1-2):12-8

Read all references and abstracts

Autism (positive symptoms such as repetitive behavior): the association with lower vasopressin levels (1 reference)
  1. Zhang HF, Dai YC, Wu J, Jia MX, Zhang JS, Shou XJ, Han SP, Zhang R, Han JS. Plasma oxytocin and arginine-vasopressin levels in children with autism spectrum disorder in China: associations with symptoms. Neurosci Bull. 2016 Oct;32(5):423-32.
Schizophrenia (negative symptoms): the improvement with vasopressin/desmopressin treatment (1 reference)
  1. Brambilla F, Bondiolotti GP, Maggioni M, Sciascia A, Grillo W, Sanna F, Latina A, Picotti GB. Vasopressin (DDAVP) therapy in chronic schizophrenia: effects on negative symptoms and memory. Neuropsychobiology. 1989;20(3):113-9
Sleep disorder: the improvement with vasopressin/desmopressin treatment (19 references)
  1. Kim SO, Yu HS, Kwon D. Efficacy of Desmopressin to Treat Nocturnal Polyuria in Elderly Men: Effects on Sleep Quality. Urol Int. 2016;96(4):438-42.
  2. Van Herzeele C, Dhondt K, Roels SP, Raes A, Hoebeke P, Groen LA, Vande Walle J. Desmopressin (melt) therapy in children with monosymptomatic nocturnal enuresis and nocturnal polyuria results in improved neuropsychological functioning and sleep. Pediatr Nephrol. 2016 Sep;31(9):1477-84.
  3. Mun JH, Kim SO2, Yu HS, Chung HS, Kwon D. Effects of desmopressin for the treatment of nocturnal polyuria in elderly women: impact on related sleep quality. Can Urol Assoc J. 2015 Nov-Dec;9(11-12):E770-4.
  4. Berges R, Höfner K, Gedamke M, Oelke M. Impact of desmopressin on nocturia due to nocturnal polyuria in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). World J Urol. 2014 Oct;32(5):1163-70.
  5. Ahmed AF, Maarouf A, Shalaby E, Gabr AH, Shahin A, Ghobish A. The impact of adding low-dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World J Urol. 2015 May;33(5):649-57.

Read all references and abstracts

Sleep disorders: no improvement (in quality of sleep) with vasopressin/desmopressin treatment (1 reference)
  1. Rahm C, Schulz-Juergensen S, Eggert P. Effects of desmopressin on the sleep of children suffering from enuresis. Acta Paediatr. 2010 Jul;99(7):1037-41.
Nocturia; the association with lower vasopressin levels (4 references)
  1. Natsume O. A clinical investigation of nocturnal polyuria in patients with nocturia: a diurnal variation in arginine vasopressin secretion and its relevance to mean blood pressure. J Urol. 2006 Aug;176(2):660-4
  2. Sakakibara R, Uchiyama T, Liu Z, Yamamoto T, Ito T, Yamanishi T, Hattori T. Nocturnal polyuria with abnormal circadian rhythm of plasma arginine vasopressin in post-stroke patients. Intern Med. 2005 Apr;44(4):281-4
  3. Asplund R. Diuresis pattern, plasma vasopressin and blood pressure in healthy elderly persons with nocturia and nocturnal polyuria. Neth J Med. 2002 Aug;60(7):276-80
  4. Kikuchi Y. Participation of atrial natriuretic peptide levels and arginine vasopressin in aged persons with nocturia. Nippon Hinyokika Gakkai Zasshi. 1995 Nov;86(11):1651-9
Nocturia: the improvement with vasopressin/desmopressin treatment (23 references)
  1. Weiss JP, van der Meulen EA, Juul KV. Low-dose desmopressin orally disintegrating tablet: suggested clinically meaningful benefit in patients with nocturia due to nocturnal polyuria. Eur Urol Focus. 2018 Nov 20. pii: S2405-4569(18)30333-X.
  2. Chen SL, Huang YH, Hung TW, Ou YC. Comparison of nocturia response to desmopressin treatment in elderly men with and without nocturnal polyuria in real-life practice. Int J Clin Pract. 2016 May;70(5):372-9.
  3. Sand PK, Dmochowski RR, Reddy J, van der Meulen EA. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel group study. J Urol. 2013 Sep;190(3):958-64.
  4. Weiss JP, Herschorn S, Albei CD, van der Meulen EA. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel group study. J Urol. 2013 Sep;190(3):965-72.
  5. Weiss JP, Zinner NR, Klein BM, Nørgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn. 2012 Apr;31(4):441-7.

Read all references and abstracts

Hemorrhages: the improvement with vasopressin/desmopressin treatment (7 references)
  1. Kongnyuy EJ, Wiysonge CS. Interventions to reduce haemorrhage during myomectomy for fibroids. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005355
  2. Martin-Hirsch PL, Kitchener H. Interventions for preventing blood loss during the treatment of cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2000;(2):CD001421
  3. Jelínek J, Huvar I, Roztocil A, Pilka L. Hemostasis using vasopressin analogs during conization of the uterine cervix and minor vaginal operations. Ceska Gynekol. 1997 Jun;62(3):142-4
  4. Mariana G, Ciavarella N, Mazzucconi MG, Antoncecchi S, Solinas S, Ranieri P, Pettini P, Agrestini F, Mandelli F. Evaluation of the effectiveness of DDAVP in surgery and in bleeding episodes in haemophilia and von Willebrand’s disease. A study on 43 patients. Clin Lab Haematol. 1984;6(3):229-38
  5. Bolton-Maggs P, Wilkinson LS. Mild bleeding disorders: review of 120 patients. Clin Lab Haematol. 1984;6(3):247-56

Read all references and abstracts

Hypercholesterolemia: the improvement with vasopressin treatment in rats (1 reference)
  1. Caisová D, Stajner A, Sůva J. Modification of fat and carbohydrate metabolism by neurohypophyseal hormones. I. Effect of lysine-vasopressin on non-esterified fatty acid, glucose, triglyceride and cholesterol levels in the serum of female rats. Endokrinologie. 1980 Dec;76(3):315-25
Arterial hypertension: the association with lower vasopressin levels (2 references)
  1. Asplund R. Diuresis pattern, plasma vasopressin and blood pressure in healthy elderly persons with nocturia and nocturnal polyuria. Neth J Med. 2002 Aug;60(7):276-80
  2. Rascher W, Weidmann E, Gross F. Vasopressin in the plasma of stroke-prone spontaneously hypertensive rats. Clin Sci (Lond). 1981 Sep;61(3):295-8
Portal and pulmonary hypertension: the improvement with vasopressin (6 references)
  1. Tayama E, Ueda T, Shojima T, Akasu K, Oda T, Fukunaga S, Akashi H, Aoyagi S. Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. Interact Cardiovasc Thorac Surg. 2007 Dec;6(6):715-9
  2. Price LC, Forrest P, Sodhi V, Adamson DL, Nelson-Piercy C, Lucey M, Howard LS. Use of vasopressin after Caesarean section in idiopathic pulmonary arterial hypertension. Br J Anaesth. 2007 Oct;99(4):552-5
  3. Wang HJ, Wong CS, Chiang CY, Yeh CC, Cherng CH, Ho ST, Wu CT. Low-dose vasopressin infusion can be an alternative in treating patients with refractory septic shock combined with chronic pulmonary hypertension–a case report. Acta Anaesthesiol Sin. 2003 Jun;41(2):77-80
  4. Ohnishi K, Saito M, Nakayama T, Hatano H, Okuda K. Effects of vasopressin on portal hemodynamics in patients with portal hypertension. Am J Gastroenterol. 1987 Feb;82(2):135-8
  5. Kaufman SL, Maddrey WC, Harrington DP, White RI Jr. Hemodynamic effects of superior mesenteric arterial and intravenous vasopressin infusions in patients with portal hypertension. Invest Radiol. 1977 May-Jun;12(3):210-4

Read all references and abstracts

Cardiac arrest: the improvement with vasopressin (1 reference)
  1. Aung K, Htay T. Vasopressin for cardiac arrest: a systematic review and meta-analysis. Arch Intern Med. 2005 Jan 10;165(1):17-24
Obesity: the association with low vasopressin levels (7 references)
  1. Gavaldà-Manso M, Jimenez-Marrero S, Cainzos-Achirica M, Garay A, Enjuanes C, Yun S, Diez C, Gonzalez-Costello J, Tajes M, Farre N, Duran X, Comin-Colet J. Reduced levels of vasopressin, an independent mechanism in the obesity paradox in patients with chronic heart failure: Insights from the DAMOCLES study. Int J Cardiol. 2019 Feb 1;276:171-176.
  2. Coiro V, Capretti L, Speroni G, Castelli A, Bianconi L, Cavazzini U, Marcato A, Volpi R, Chiodera P. Increase by naloxone of arginine vasopressin and oxytocin responses to insulin-induced hypoglycemia in obese men. J Endocrinol Invest. 1990 Oct;13(9):757-63.
  3. Chiodera P, Capretti L, Davoli C, Caiazza A, Bianconi L, Coiro V. Effect of obesity and weight loss on arginine vasopressin response to metoclopramide and nicotine from cigarette smoking. Metabolism. 1990 Aug;39(8):783-6.
  4. Coiro V, Chiodera P. Effect of obesity and weight loss on the arginine vasopressin response to insulin-induced hypoglycaemia. Clin Endocrinol (Oxf). 1987 Aug;27(2):253-8.
  5. Chiodera P, Capretti L, Davoli C, Caiazza A, Bianconi L, Coiro V. Effect of obesity and weight loss on arginine vasopressin response to metoclopramide and nicotine from cigarette smoking. Metabolism. 1990 Aug;39(8):783-6

Read all references and abstracts

Obesity: the association with high vasopressin levels (1 reference)
  1. Enhörning S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M, Morgenthaler NG, Nilsson PM, Melander O. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort. Int J Obes (Lond). 2013 Apr;37(4):598-603.

Get the latest International Hormone Society news delivered to your inbox.